LEADER 04006nam 22005775 450 001 9910631091003321 005 20260210144517.0 010 $a3-031-11363-2 024 7 $a10.1007/978-3-031-11363-5 035 $a(MiAaPQ)EBC7143438 035 $a(Au-PeEL)EBL7143438 035 $a(CKB)25402003700041 035 $a(OCoLC)1352092387 035 $a(BIP)084584787 035 $a(PPN)26635517X 035 $a(DE-He213)978-3-031-11363-5 035 $a(EXLCZ)9925402003700041 100 $a20221118d2022 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aInfectious Complications in Biologic and Targeted Therapies /$fedited by Carlos Cervera, Jose Maria Aguado 205 $a1st ed. 2022. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2022. 215 $a1 online resource (466 pages) 311 08$aPrint version: Cervera, Carlos Infectious Complications in Biologic and Targeted Therapies Cham : Springer International Publishing AG,c2022 9783031113628 320 $aIncludes bibliographical references and index. 327 $aOverview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- ?4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use ofCarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus. 330 $aThis book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies. 606 $aInternal medicine 606 $aInternal Medicine 606 $aControl d'infeccions$2thub 606 $aDianes farmacològiques$2thub 608 $aLlibres electrònics$2thub 615 0$aInternal medicine. 615 14$aInternal Medicine. 615 7$aControl d'infeccions 615 7$aDianes farmacològiques 676 $a615.7 676 $a616.9 702 $aCervera$b Carlos$4edt 702 $aAguado$b Jose Maria$4edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910631091003321 996 $aInfectious complications in biologic and targeted therapies$93083864 997 $aUNINA